The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia
BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated. OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate mole...
Main Author: | |
---|---|
Language: | en_US |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/2144/23731 |
id |
ndltd-bu.edu-oai-open.bu.edu-2144-23731 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-bu.edu-oai-open.bu.edu-2144-237312019-03-18T15:24:01Z The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia Smith, Catherine Mary Endocrinology Diabetes Endocrinology Hypoglycemia Bariatric surgery Post bariatric hypoglycemia BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated. OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate molecules identified in humans with PBH. METHODS: Gastric bypass patients were assigned to groups based on whether or not they suffered from hypoglycemia (PBH, n = 11; asymptomatic, n = 7). Patients underwent a mixed meal tolerance test with blood draws at baseline, 30 minutes, and 120 minutes postprandially. SOMAscan (Somalogic) was used to evaluate serum for protein levels. In parallel, mass spectrometry (Metabolon) was used to examine metabolite levels. Mice were treated with the Farnesoid X Receptor (FXR) agonist, fexaramine (Fex), or vehicle for 5 days before undergoing a glucose tolerance test (GTT). Mice were sacrificed with tissues collected immediately thereafter. PCR was performed to quantify expression of FXR target genes. A separate cohort of mice was treated with adenine or vehicle for 2 days before undergoing a GTT or an insulin tolerance test. RESULTS: FGF19 was the most significantly upregulated protein in the PBH group at all time points. At 120 minutes postprandially, FGF19 was 2.1-fold higher in the PBH group (p < 1x10-5). Adenine was >2-fold higher at all time points (p < 1x10-8). Treatment with Fex did not result in significant differences during GTT or in expression of FXR target genes. Treatment with adenine did not significantly impact glucose tolerance or insulin sensitivity between groups. CONCLUSIONS: The results of the human serum analyses established a strong foundation on which to develop a murine model of PBH. Though the mouse experiments failed to induce postprandial hypoglycemia, they have directed future experiments toward developing a murine model of PBH. 2018-07-11T00:00:00Z 2017-09-07T14:20:15Z 2017 2017-07-12T01:11:29Z Thesis/Dissertation https://hdl.handle.net/2144/23731 en_US |
collection |
NDLTD |
language |
en_US |
sources |
NDLTD |
topic |
Endocrinology Diabetes Endocrinology Hypoglycemia Bariatric surgery Post bariatric hypoglycemia |
spellingShingle |
Endocrinology Diabetes Endocrinology Hypoglycemia Bariatric surgery Post bariatric hypoglycemia Smith, Catherine Mary The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
description |
BACKGROUND: Post-bariatric hypoglycemia (PBH), a complication of gastric bypass surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the etiology of PBH has not been fully elucidated.
OBJECTIVE: To develop a murine model of PBH by experimentally modifying candidate molecules identified in humans with PBH.
METHODS: Gastric bypass patients were assigned to groups based on whether or not they suffered from hypoglycemia (PBH, n = 11; asymptomatic, n = 7). Patients underwent a mixed meal tolerance test with blood draws at baseline, 30 minutes, and 120 minutes postprandially. SOMAscan (Somalogic) was used to evaluate serum for protein levels. In parallel, mass spectrometry (Metabolon) was used to examine metabolite levels. Mice were treated with the Farnesoid X Receptor (FXR) agonist, fexaramine (Fex), or vehicle for 5 days before undergoing a glucose tolerance test (GTT). Mice were sacrificed with tissues collected immediately thereafter. PCR was performed to quantify expression of FXR target genes. A separate cohort of mice was treated with adenine or vehicle for 2 days before undergoing a GTT or an insulin tolerance test.
RESULTS: FGF19 was the most significantly upregulated protein in the PBH group at all time points. At 120 minutes postprandially, FGF19 was 2.1-fold higher in the PBH group (p < 1x10-5). Adenine was >2-fold higher at all time points (p < 1x10-8). Treatment with
Fex did not result in significant differences during GTT or in expression of FXR target genes. Treatment with adenine did not significantly impact glucose tolerance or insulin sensitivity between groups.
CONCLUSIONS: The results of the human serum analyses established a strong foundation on which to develop a murine model of PBH. Though the mouse experiments failed to induce postprandial hypoglycemia, they have directed future experiments toward developing a murine model of PBH. === 2018-07-11T00:00:00Z |
author |
Smith, Catherine Mary |
author_facet |
Smith, Catherine Mary |
author_sort |
Smith, Catherine Mary |
title |
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
title_short |
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
title_full |
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
title_fullStr |
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
title_full_unstemmed |
The development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
title_sort |
development of a mouse model of post-bariatric hyperinsulinemic hypoglycemia |
publishDate |
2017 |
url |
https://hdl.handle.net/2144/23731 |
work_keys_str_mv |
AT smithcatherinemary thedevelopmentofamousemodelofpostbariatrichyperinsulinemichypoglycemia AT smithcatherinemary developmentofamousemodelofpostbariatrichyperinsulinemichypoglycemia |
_version_ |
1719003963134574592 |